Kintara Therapeutics (NASDAQ:KTRA) Inc has announced that its chairman, Robert Hoffman, has succeeded Saiid Zarrabian as the company’s president and CEO effective November 8, 2021.
Kintara said Hoffman will continue in his role as the company's chairman, while Zarrabian will transition to lead Kintara's strategic partnerships initiative and will remain a member of its board of directors.
“Over the past few years, it was Saiid who led the effort to streamline and strengthen Kintara's operational foundation and product pipeline with the addition of REM-001, while also advancing multiple clinical trials for our platform asset VAL-083 highlighted by its participation in GCAR's GBM AGILE study,” Kintara CEO Robert Hoffman said in a statement.
READ: Kintara heads into new fiscal year with strengthened balance sheet
“This is a transformational opportunity for the Company as the GCAR study is an FDA-approved registrational trial which is cost-effective through its expense-sharing protocol that is designed to greatly accelerate VAL-083's timeline for regulatory submission perhaps by up to 18 months,” Hoffman added.
Hoffman, who has been a Kintara director since April 2018 and its chairman since June 2018, currently serves as a board member of Aslan Pharmaceuticals, Inc, Antibe Therapeutics, Inc, and Saniona AB.
Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.
The San Diego, California-based company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer (CMBC).
Contact Sean at sean@proactiveinvestors.com